Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers

Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge. However, conditions for nAb-mediated protection after vaccination have not been established. Here, we selected groups of 6...

Full description

Bibliographic Details
Main Authors: Pauthner, Matthias G., Nkolola, Joseph P., Havenar-Daughton, Colin, Murrell, Ben, Reiss, Samantha M., Bastidas, Raiza, Prévost, Jérémie, Nedellec, Rebecca, Bredow, Benjamin von, Abbink, Peter, Cottrell, Christopher A., Kulp, Daniel W. K, Tokatlian, Talar, Nogal, Bartek, Bianchi, Matteo, Li, Hui, Lee, Jeong Hyun, Butera, Salvatore T., Evans, David T., Hangartner, Lars, Finzi, Andrés, Wilson, Ian A., Wyatt, Richard T., Irvine, Darrell J., Irvine, Darrell J, Schief, William R., Ward, Andrew B., Sanders, Rogier W., Crotty, Shane, Shaw, George M., Barouch, Dan H., Burton, Dennis R.
Other Authors: Ragon Institute of MGH, MIT and Harvard
Format: Article
Language:English
Published: Elsevier BV 2020
Online Access:https://hdl.handle.net/1721.1/126817
Description
Summary:Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge. However, conditions for nAb-mediated protection after vaccination have not been established. Here, we selected groups of 6 rhesus macaques with either high or low serum nAb titers from a total of 78 animals immunized with recombinant native-like (SOSIP) Env trimers. Repeat intrarectal challenge with homologous tier 2 SHIV BG505 led to rapid infection in unimmunized and low-titer animals. High-titer animals, however, demonstrated protection that was gradually lost as nAb titers waned over time. An autologous serum ID 50 nAb titer of ∼1:500 afforded more than 90% protection from medium-dose SHIV infection. In contrast, antibody-dependent cellular cytotoxicity and T cell activity did not correlate with protection. Therefore, Env protein-based vaccination strategies can protect against hard-to-neutralize SHIV challenge in rhesus macaques by inducing tier 2 nAbs, provided appropriate neutralizing titers can be reached and maintained.